In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection

Abstract COVID-19 has currently become the biggest challenge in the world. There is still no specific medicine for COVID-19, which leaves a critical gap for the identification of new drug candidates for the disease. Recent studies have reported that the small-molecule enoxacin exerts an antiviral ac...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Amirhossein Ahmadi, Sharif Moradi
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/5ca25b6c50e4471d8b5bd1556e481349
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!